When Patients Win, We All Win

Advancing
a New Front
in the War against Cancer

Provectus Biopharmaceuticals is
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects

EXPLORE OUR CLINICAL TRIALS


PV-10

An Investigational Drug for Cancer

PH-10

An Investigational Drug for Psoriasis and Atopic Dermatitis

IN THE MEDIA

February 8, 2016

Webcast: BIO CEO and Investor Conference 2016

Provectus will present today at 3:00pm EST at the 18th Annual BIO CEO and Investor Conference.

January 29, 2015

Investing in Cancer Treatments: 5 Small-cap Companies Researching Drug Treatments

An Investment News Network article reports on a handful of select small-cap companies working on cancer treatments.

December 23, 2015

100 year old chemical could be the future of cancer treatment

In an interview with Peter Culpepper, a Pharmafile article discusses the history, status, and projected future use of Provectus' investigationl anti-cancer drug PV-10.

November 4, 2015

Webcast: Q3 2015 Quarterly Business Update Conference Call

Provectus will hold its quarterly business update conference call at 5 p.m. (EST) November 5, 2015 to provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors.

October 7, 2015

Provectus Biopharmaceuticals to start two Phase III dermatology trials mid-2016, will entertain CRO pitches - exec

A BioPharm Insight article reports that Provectus' is planning two Phase III trials of PH-10 to begin in mid-2016.

October 7, 2015

PV-10 shows potential in hepatocellular carcinoma and metastatic liver disease

P&T meeting highlights for ESMO 17th World Congress on Gastrointestinal Cancer includes coverage of the Phase 1 study of PV-10 for chemoablation of hepatocellular cancer and cancer metastatic to the liver.

September 30, 2015

The Forecast Is Bright: Recent Advances in Melanoma Treatment

An article appearing in the Journal of Cutaneous Medicine and Surgery discusses recent advances in the treatment of advanced melanoma.

September 28, 2015

Provectus to study novel drug combined with Keytruda for stage IV melanoma

A Healio Dermatology article covers news that Provectus has initiated a Phase 1b/2 clinical trial of PV-10 in combination with Keytruda® for the treatment of stage IV melanoma.

September 9, 2015

PV-10 shows potential in hepatocellular carcinoma and metastatic liver disease

A report on PV-10 liver study data appears at the top of an Oncology News article entitled "Reports from ESMO 17th World Congress on Gastrointestinal Cancer."

August 27, 2015

Provectus Biopharmaceuticals Announces Joint Patent for Oncology Therapy PV-10

Investing News Network recently published an article in the Life Science section covering news of the grant by the US PTO of a patent, shared jointly by Provectus and Pfizer, covering PV-10 when used in combination with select melanoma and liver cancer therapies.

August 6, 2015

Webcast: Q2 2015 Quarterly Business Update Conference Call

Provectus will hold its quarterly business update conference call at 4 p.m. (EDT) August, 2015 to provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors.

July 27, 2015

Overview of Intralesional Therapy in Melanoma

At the World Cutaneous Malignancies Congress meeting at Personalized Medicine in Oncology's PMO Live 2015 conference, a presentation entitled "Overview of Intralesional Therapy in Melanoma" was presented by Dr. Sanjiv Agarwala.

July 17, 2015

Oncolytic Immunotherapy in Melanoma: It's Not All About PD-1

In an article appearing in The ASCO Post, Robert Andtbacka, MD discusses the use of intralesional anti-cancer agents that induce a systemic immune response.

July 14, 2015

New chemoablative approach for hepatocellular carcinoma and metastatic liver disease

A Pharmiweb article discusses data from the phase 1 trial of PV-10 for liver cancer that includes two patients that demonstrated non-existent liver cancer after a single injection of PV-10.

July 13, 2015

ESMO GI provides new insights into HCC and metastatic liver cancer

An article appearing in Medical News Today discusses studies of investigational drugs for treating HCC and metastatic liver cancer that were presented at ESMO GI 2015.

July 8, 2015

BI works with Provectus on China candidate

An article appearing on FiercePharmaAsia reports that Boehringer Ingelheim will work with Provectus to register cancer candidate PV-10 in China in return for priority rights in the country on commercialization.

July 8, 2015

Trials Show Promise for Locoregional Treatment for Hepatocellular Carcinoma and Liver Metastases

An article appearing on DocGuide reports on promising clinical studies of locoregional liver cancer treatments that were presented at the 2015 ESMO World Congress on Gastrointestinal Cancer.

July 7, 2015

PV-10 shows potential in hepatocellular carcinoma and metastatic liver disease

An eCancer News article reports on data from the phase 1 study of PV-10 for liver cancer that was recently presented at ESMO 2015.

July 7, 2015

Provectus partners with big pharma for its PV-10 drug

An article appearing in the Knoxville News Sentinel covers news of Provectus partnering with global pharmaceutical company Boehringer Ingelheim to help bring to market its investigative drug for cancer, PV-10, in mainland China, Hong Kong and Taiwan.

July 6, 2015

Provectus Signs LOI for Cancer Drug with Boehringer Ingelheim China

ChinaBio Today reports on Provectus - Boehringer Ingelheim letter of intent to collaborate on bringing PV-10 for melanoma and cancers of the liver to market in China.

more...

PRESS RELEASES

February 10, 2016

Provectus Biopharmaceuticals to Host Fourth Quarter, Year-End 2015 Conference Call Thursday, March 10, 2016, at 4 PM EST

Provectus today announced that it will host its fourth quarter and year-end 2015 conference call on Thursday, March 10, 2016, at 4:00 p.m. Eastern Standard Time.

February 3, 2016

Data on Immunology Effects of Provectus Biopharmaceuticals PV-10 in Colon Cancer Presented at 11th Annual ASC Meeting

Provectus today announced data discussing the immunologic effects of PV-10 on colon cancer cells were presented yesterday at the 11th Annual Academic Surgical Congress in Jacksonville, Florida.

February 2, 2016

Provectus Biopharmaceuticals to Present at 18th Annual BIO CEO & Investor Conference

Provectus today announced that it will present at the 18th Annual BIO CEO & Investor Conference.

January 22, 2016

Provectus Biopharmaceuticals Announces Immunology Data on PV-10 in Colon Cancer to Be Presented at 11th Annual ASC Meeting

Provectus today announced that an abstract discussing the immunologic effects of PV-10 on colon cancer cells has been accepted for presentation at the 11th Annual Academic Surgical Congress to be held February 2-4, 2016, at the Hyatt Regency in Jacksonville, Florida.

January 12, 2016

Provectus Biopharmaceuticals Confirms First Patients Dosed in Trials of PV-10 for Melanoma

Provectus today confirmed that patients have been dosed in both its Phase 3 clinical trial of PV-10, Provectus' novel investigational drug for cancer, for Stage III locally advanced cutaneous melanoma and its Phase 1b/2 clinical trial of PV-10 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with Stage IV melanoma. In addition, the Company confirmed that it continues to enroll patients in all of its active oncology studies.

December 16, 2015

Provectus Biopharmaceuticals, Inc. to Present at Biotech Showcase™ 2016 on Wednesday January 13, 2016 at 3:30 PM Pacific Time

Provectus today announced that it will present at Biotech Showcase™ 2016. The Company will summarize its business operations and discuss PV-10, its novel investigational drug for cancer, and PH-10, its topical investigational drug for dermatology.

November 5, 2015

Provectus Biopharmaceuticals Reports Immune Mechanism of Action Data for PV-10 Presented at Society for Immunotherapy of Cancer Annual Meeting Authored by Researchers at Moffitt Cancer Center

Provectus today announced that researchers from Moffitt Cancer Center in Tampa, Florida, presented a poster titled, "Intralesional Rose Bengal in Melanoma Elicits Tumor Immunity via High Mobility Group Box 1," at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting in National Harbor, Maryland.

November 5, 2015

Provectus Biopharmaceuticals Reports Third Quarter 2015 Financial Results

Provectus today announced its results of operations and financial condition for the third quarter ended September 30, 2015.

October 20, 2015

Provectus Biopharmaceuticals Will Hold Its 2015 Third Quarter Business Update Conference Call on Thursday, November 5, 2015, at 5 PM Eastern Standard Time

Provectus announced today that it will hold its 2015 third quarter business update conference call at 5 pm Eastern Standard Time on Thursday, November 5, 2015.

September 29, 2015

Provectus Biopharmaceuticals Reports Publication of Review Paper on PV-10 Tumor Ablation and Immune Stimulation

Provectus today reported that the Journal of Clinical and Cellular Immunology has published a paper titled, "The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses."

September 23, 2015

Provectus Biopharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial to Study PV-10 in Combination with Immune Check Point Inhibitor Pembrolizumab

Provectus today announced it has completed development of the protocol for Phase1b/2 testing of its investigational cancer drug PV-10 in combination with pembrolizumab in patients with Stage IV melanoma.

September 21, 2015

Provectus Biopharmaceuticals Completes Patient Accrual for PH-10 Phase 2 Clinical Study of Cellular and Immunologic Changes in the Skin

Provectus today announced that it has completed patient accrual for its phase 2 study of the cellular and immunologic changes in the skin of patients receiving PH-10, an investigational topical treatment for atopic dermatitis and psoriasis.

August 18, 2015

Pfizer, Provectus Biopharmaceuticals Awarded US Patent Protecting Use of PV-10 as Part of Combination Therapy for Cancer

Provectus today announced that it has received a patent from the US Patent and Trademark Office, U.S. Patent number 9,107,887. The patent protects the use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver.

August 6, 2015

Provectus Biopharmaceuticals Reports Second Quarter 2015 Financial Results

Provectus today announced its results of operations and financial condition for the second quarter ended June 30, 2015.

July 22, 2015

Provectus Biopharmaceuticals Will Hold Its 2015 Second Quarter Business Update Conference Call on Thursday, August 6, 2015, at 4 PM Eastern Daylight Time

Provectus announced today that it will hold its 2015 second quarter business update conference call at 4 pm Eastern Daylight Time on Thursday, August 6, 2015.

July 15, 2015

Provectus Biopharmaceuticals, Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-Think Pharmaceutical Co., Ltd Continue Search for Agreement on PV-10 Use in China

Provectus announced that it continues to work with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-Think Pharmaceutical Co., Ltd to reach an agreement on PV-10 use in China.

July 6, 2015

Provectus Biopharmaceuticals' Phase 1 PV-10 Data on Liver Cancer Presented at 6th Asia-Pacific Primary Liver Cancer Expert Meeting

Provectus announced today that data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma (HCC) and cancer metastatic to the liver was presented on July 3, 2015 at the 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015) in Osaka, Japan.

July 2, 2015

Provectus Biopharmaceuticals Signs Letter of Intent with Boehringer Ingelheim (China) to Collaborate in Bringing PV-10 to Market in China

Provectus announced today that it has signed a Letter of Intent (the "LOI") with Boehringer Ingelheim (China) Investment Co. Ltd. ("Boehringer").

July 2, 2015

Provectus Biopharmaceuticals' Data on PV-10 for Chemoablation of Liver Cancers Presented at ESMO 17th World Congress on Gastrointestinal Cancer

Provectus announced that data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma (HCC) and cancer metastatic to the liver was presented at the ESMO 17th World Congress on Gastrointestinal Cancer (ESMO-GI).

June 26, 2015

AAPI Honors Provectus Biopharmaceuticals During 33rd Annual Convention and Scientific Assembly

The American Association of Physicians of Indian Origin ("AAPI") honored Provectus Biopharmaceuticals, Inc. at a gala during the AAPI's 33rd Annual Convention and Scientific Assembly on Friday, June 19, 2015.

more...